An acne medication could have a favorably and unintended benefit to multiple sclerosis patients.
A common acne medicine called minocycline can reduce the rate of multiple sclerosis progression in patients who are at early stages of the disease, according to a Phase 3 clinical trial.
The finding was from the MinoCIS trial (NCT00666887) of minocycline, which goes by the brand name Mynocan and other labels. Canadian researchers published the study, “Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis,” in the New England Journal of Medicine.
The multicenter MinoCIS trial included 142 participants between the ages of 18 and 60 who displayed the first signs of what was suspected to be MS 180 days before starting treatment. The patients were randomized to receive either 100 mg of oral minocycline twice a day or a placebo.
Read full article: Multiple Sclerosis Progression Rate Can Be Reduced with Acne Treatment
|Read Full Article: Multiple Sclerosis Progression Rate Can Be Reduced with Acne Treatment|